Ray KK, et al. - In patients with or without diabetes, researchers analyzed the impacts of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome (myocardial infarction or unstable angina). For this prespecified analysis of the ODYSSEY OUTCOMES randomized controlled trial, they compared alirocumab vs placebo in patients who had been admitted to hospital with an acute coronary syndrome 1–12 months before randomization and who had raised concentrations of atherogenic lipoproteins, despite the use of high-intensity statins. According to findings, alirocumab therapy targeting an LDL cholesterol concentration of 0.65–1.30 mmol/L after a recent acute coronary syndrome produced about twice the absolute decline in cardiovascular events among patients with diabetes as in those without. The risk of new-onset diabetes was not increased by treatment with alirocumab.